About us
- >
- About us >
- Information >
- Announcement
2022-12-26
ENERGI-F703EB has received a certification letter from the Office of Orphan Products Development (OOPD) of the US Food and Drug Administration (FDA),
We are pleased to announce that on December 26, 2022, our company received notification from our consulting firm that our investigational new drug, ENERGI-F703EB, has been granted the Orphan Drug Designation (ODD) by the Office of Orphan Products Development (OOPD) at the U.S. Food and Drug Administration (FDA).